CIK 0001063537
RIBT RiceBran Technologies
Insider trading from SEC Form 4. Last filing Jan 8, 2024.
In brief
RiceBran Technologies (RIBT) has 2 SEC Form 4 filings on file from 2 insiders, the latest filed on Jan 8, 2024. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Signals
Open-market buys and sells at RiceBran Technologies, scored.
Transactions
Every row filed, 2 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 31, 2023 | David I. Chemerow director | AGrant or award Deferred Stock Unitsderivative | +65,218 | $0.00 | $0 | 198,545 | Jan 8, 2024 |
| Dec 31, 2023 | Brent D Rosenthal director | AGrant or award Deferred Stock Unitsderivative | +58,696 | $0.00 | $0 | 193,983 | Jan 8, 2024 |
Questions about RIBT
Answered from the filings on this page, as of the latest one.
Are insiders buying RIBT?
No. In the last 90 days no insider at RiceBran Technologies bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade RIBT on the open market?
No open-market trade has been scored at RiceBran Technologies. The latest Form 4 on file was filed on Jan 8, 2024 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at RiceBran Technologies?
2 people have filed a Form 4 at RiceBran Technologies, among them David I. Chemerow (director), Brent D Rosenthal (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.